Tarsus Pharmaceuticals, Inc.

NasdaqGS:TARS Stok Raporu

Piyasa değeri: US$1.2b

Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Tarsus Pharmaceuticals Yönetim

Yönetim kriter kontrolleri 4/4

Tarsus Pharmaceuticals' CEO'su Bobby Azamian, Nov2016 tarihinde atandı, in görev süresi 7.92 yıldır. in toplam yıllık tazminatı $ 3.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 19.8% maaş ve 80.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 2.25% ine doğrudan sahiptir ve bu hisseler $ 28.17M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.4 yıl ve 4 yıldır.

Anahtar bilgiler

Bobby Azamian

İcra Kurulu Başkanı

US$3.1m

Toplam tazminat

CEO maaş yüzdesi19.8%
CEO görev süresi7.9yrs
CEO sahipliği2.3%
Yönetim ortalama görev süresi3.4yrs
Yönetim Kurulu ortalama görev süresi4yrs

Son yönetim güncellemeleri

Recent updates

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Sep 05
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Stocks Shoot Up 35% But Its P/S Still Looks Reasonable

Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment

Aug 20

With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Jun 26
With A 26% Price Drop For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) You'll Still Get What You Pay For

Following Up On Tarsus Pharmaceuticals

May 28

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

May 11
Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Tarsus Pharmaceuticals: A Strong Launch For An Under The Radar Name

Mar 08

Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Mar 03
Rainbows and Unicorns: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Analysts Just Became A Lot More Optimistic

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 01
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

Feb 28
Is Tarsus Pharmaceuticals (NASDAQ:TARS) A Risky Investment?

New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Nov 12
New Forecasts: Here's What Analysts Think The Future Holds For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

Aug 16
What Does The Future Hold For Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? These Analysts Have Been Cutting Their Estimates

CEO Tazminat Analizi

Bobby Azamian'un ücretlendirmesi Tarsus Pharmaceuticals'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

-US$150m

Mar 31 2024n/an/a

-US$148m

Dec 31 2023US$3mUS$620k

-US$136m

Sep 30 2023n/an/a

-US$108m

Jun 30 2023n/an/a

-US$91m

Mar 31 2023n/an/a

-US$65m

Dec 31 2022US$4mUS$590k

-US$62m

Sep 30 2022n/an/a

-US$63m

Jun 30 2022n/an/a

-US$56m

Mar 31 2022n/an/a

-US$44m

Dec 31 2021US$7mUS$550k

-US$14m

Sep 30 2021n/an/a

-US$10m

Jun 30 2021n/an/a

-US$5m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$3mUS$437k

-US$27m

Sep 30 2020n/an/a

-US$17m

Jun 30 2020n/an/a

-US$7m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$416kUS$300k

-US$5m

Tazminat ve Piyasa: Bobby 'nin toplam tazminatı ($USD 3.13M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Bobby 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Bobby Azamian

7.9yrs

Görev süresi

US$3,130,332

Tazminat

Dr. Bobak R. Azamian, also known as Bobby, MD, Ph D, DPhil, is Co-Founder of Tarsus Pharmaceuticals, Inc. and serves as its President since November 2016. He serves as Chief Executive Officer at Tarsus Pha...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Bobak Azamian
Co-Founder7.9yrsUS$3.13m2.25%
$ 27.6m
Jeffrey S. Farrow
CFO & Chief Strategy Officer1.5yrsUS$3.99m0.048%
$ 585.2k
Seshadri Neervannan
Chief Operating Officer4.3yrsUS$1.74m0.17%
$ 2.1m
Elizabeth Lin
Chief Medical Advisor & Director4.2yrsUS$180.21k0.087%
$ 1.1m
David Nakasone
Head of Investor Relations3.1yrsVeri yokVeri yok
Bryan Wahl
General Counsel & Corporate Secretary3.8yrsUS$2.53m0.11%
$ 1.3m
Adrienne Kemp
Senior Director of Corporate Communications2.5yrsVeri yokVeri yok
Matthew Rossen
Vice President of Marketing2.8yrsVeri yokVeri yok
Scott Youmans
Vice President of Sales2.6yrsVeri yokVeri yok
Dianne Whitfield
Chief Human Resources Officer3.8yrsUS$3.21m0.090%
$ 1.1m
Aziz Mottiwala
Chief Commercial Officer4.2yrsVeri yok0.14%
$ 1.7m
Cara Miller
Senior Vice President of Corporate Affairsless than a yearVeri yokVeri yok

3.4yrs

Ortalama Görev Süresi

46yo

Ortalama Yaş

Deneyimli Yönetim: TARS 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.4 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Bobak Azamian
Co-Founder7.8yrsUS$3.13m2.25%
$ 27.6m
Elizabeth Lin
Chief Medical Advisor & Director2.8yrsUS$180.21k0.087%
$ 1.1m
William Link
Independent Director7.8yrsUS$183.33k0.47%
$ 5.7m
Wendy Yarno
Lead Independent Director3.9yrsUS$265.83k0.027%
$ 334.0k
Bhaskar Chaudhuri
Independent Director4.8yrsUS$178.58k0.014%
$ 172.6k
Scott William Morrison
Independent Director2yrsUS$186.46k0.016%
$ 194.1k
Rosemary Crane
Independent Director3.2yrsUS$183.71k0.014%
$ 172.6k
Andrew Goldberg
Independent Director4.2yrsUS$171.71k0.017%
$ 204.9k

4.0yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: TARS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4 yıldır).